192 related articles for article (PubMed ID: 9336153)
21. How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?
Teo PM; Kwan WH; Chan AT; Lee WY; King WW; Mok CO
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):897-913. PubMed ID: 9531376
[TBL] [Abstract][Full Text] [Related]
22. The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis.
Yao JJ; Jin YN; Wang SY; Zhang F; Zhou GQ; Zhang WJ; Zhi-Bin ; Cheng ; Ma J; Qi ZY; Sun Y
BMC Cancer; 2018 Jul; 18(1):740. PubMed ID: 30012115
[TBL] [Abstract][Full Text] [Related]
23. The effect of nodal status on determinants of initial treatment response and patterns of relapse-free survival in nasopharyngeal carcinoma.
Tang SG; See LC; Chen WC; Tsang S; Chang JT; Hong JH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):867-73. PubMed ID: 10863054
[TBL] [Abstract][Full Text] [Related]
24. The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx: an analysis of 1301 patients.
Kwong D; Sham J; Choy D
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1029-36. PubMed ID: 7961008
[TBL] [Abstract][Full Text] [Related]
25. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control.
Sanguineti G; Geara FB; Garden AS; Tucker SL; Ang KK; Morrison WH; Peters LJ
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):985-96. PubMed ID: 9169804
[TBL] [Abstract][Full Text] [Related]
26. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
27. Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma.
Lu JJ; Kong L; Shakespeare TP; Loh KS; Zhang Q; Tan KS; Lee KM
Oral Oncol; 2008 Jul; 44(7):703-9. PubMed ID: 18061528
[TBL] [Abstract][Full Text] [Related]
28. Outcome and long-term efficacy of four facio-cervical fields conformal radiotherapy for nasopharyngeal carcinoma.
Fangzheng W; Chuner J; Lei W; Weijun C; Min X; Quanquan S; Tongxin L; Aizawa R; Sakamoto M; Zhenfu F
Oncotarget; 2017 Jun; 8(24):39756-39765. PubMed ID: 28055973
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
[TBL] [Abstract][Full Text] [Related]
30. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
[TBL] [Abstract][Full Text] [Related]
31. Nasopharyngeal carcinoma: Experience and treatment outcome with radical conformal radiotherapy from a tertiary care center in India.
Kunheri B; Agarwal G; Sunil PS; Nair AR; Pushpaja KU
Indian J Cancer; 2017; 54(3):502-507. PubMed ID: 29798947
[TBL] [Abstract][Full Text] [Related]
32. Long-term Outcomes Following Radiotherapy for Adolescent Patients With Nonmetastatic WHO Type III Nasopharyngeal Carcinoma.
Greenwalt JC; Indelicato DJ; Amdur RJ; Morris CG; Kirwan JM; Mendenhall WM
Am J Clin Oncol; 2016 Dec; 39(6):581-585. PubMed ID: 24937634
[TBL] [Abstract][Full Text] [Related]
33. The Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma.
Yoon HI; Kim KH; Lee J; Roh YH; Yun M; Cho BC; Lee CG; Keum KC
Cancer Res Treat; 2016 Jul; 48(3):928-41. PubMed ID: 26693913
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy.
Mao YP; Tang LL; Chen L; Sun Y; Qi ZY; Zhou GQ; Liu LZ; Li L; Lin AH; Ma J
Chin J Cancer; 2016 Dec; 35(1):103. PubMed ID: 28031050
[TBL] [Abstract][Full Text] [Related]
35. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
[TBL] [Abstract][Full Text] [Related]
36. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
[TBL] [Abstract][Full Text] [Related]
37. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment Serum Lactate Dehydrogenase Level as an Independent Prognostic Factor of Nasopharyngeal Carcinoma in the Intensity-Modulated Radiation Therapy Era.
Chen Z; Guo Q; Lu T; Lin S; Zong J; Zhan S; Xu L; Pan J
Med Sci Monit; 2017 Jan; 23():437-445. PubMed ID: 28120819
[TBL] [Abstract][Full Text] [Related]
39. T1 nasopharyngeal carcinoma: the effect of waiting time on tumor control.
Lee AW; Chan DK; Fowler JF; Poon YF; Law SC; Foo W; O SK; Tung SY; Cheung FK; Ho JH
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1111-7. PubMed ID: 7961019
[TBL] [Abstract][Full Text] [Related]
40. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3.
Terhaard CH; Kal HB; Hordijk GJ
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):62-9. PubMed ID: 15850903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
